Aclaris Therapeutics Inc (NASDAQ: ACRS) is 13.33% higher on its value in year-to-date trading and has touched a low of $0.59 and a high of $12.93 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRS stock was last observed hovering at around $1.20 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $1.19, the stock is 0.00% and 4.55% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.95 million and changing -0.83% at the moment leaves the stock -78.29% off its SMA200. ACRS registered -90.18% loss for a year compared to 6-month loss of -81.97%. The firm has a 50-day simple moving average (SMA 50) of -$1.07 and a 200-day simple moving average (SMA200) of $0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.46% gain in the last 1 month and extending the period to 3 months gives it a 36.80%, and is -0.83% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.26% over the week and 7.31% over the month.
Aclaris Therapeutics Inc (ACRS) has around 91 employees, a market worth around $84.30M and $31.25M in sales. Profit margin for the company is -283.15%. Distance from 52-week low is 101.63% and -90.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.21%).
Aclaris Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.31 with sales reaching $2.55M over the same period.The EPS is expected to grow by 20.21% this year, but quarterly earnings will post -68.70% year-over-year.
155 institutions hold shares in Aclaris Therapeutics Inc (ACRS), with institutional investors hold 99.22% of the company’s shares. The shares outstanding are 70.89M, and float is at 64.47M with Short Float at 9.05%. Institutions hold 96.59% of the Float.
The top institutional shareholder in the company is Wellington Management Group, LLP with over 7.64 million shares valued at $79.2 million. The investor’s holdings represent 10.79% of the ACRS Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 5.59 million shares valued at $58.01 million to account for 7.90% of the shares outstanding. The other top investors are RA Capital Management, L.P. which holds 4.4 million shares representing 6.21% and valued at over $45.61 million, while Rock Springs Capital Management, LP holds 5.60% of the shares totaling 3.96 million with a market value of $41.08 million.
Aclaris Therapeutics Inc (ACRS) Insider Activity
A total of 4 insider transactions have happened at Aclaris Therapeutics Inc (ACRS) in the last six months, with sales accounting for 2 and purchases happening 2 times. The most recent transaction is an insider sale by Monahan Joseph, the company’s Chief Scientific Officer. SEC filings show that Monahan Joseph sold 6,000 shares of the company’s common stock on Oct 23 at a price of $5.08 per share for a total of $30460.0. Following the sale, the insider now owns 0.13 million shares.
Aclaris Therapeutics Inc disclosed in a document filed with the SEC on Sep 06 that Balthaser Kevin (Chief Financial Officer) bought a total of 9,490 shares of the company’s common stock. The trade occurred on Sep 06 and was made at $7.90 per share for $74971.0. Following the transaction, the insider now directly holds 15461.0 shares of the ACRS stock.
Still, SEC filings show that on Aug 28, Loerop James (Chief Business Officer) acquired 14,705 shares at an average price of $6.80 for $99959.0. The insider now directly holds 21,688 shares of Aclaris Therapeutics Inc (ACRS).
Aclaris Therapeutics Inc (ACRS): Who are the competitors?
One of the company’s main competitors (and peers) include Ono Pharmaceutical Co. Ltd. ADR (OPHLY) that is trading -20.90% down over the past 12 months.Omeros Corp. (OMER) lies in the list of competitors of the Aclaris Therapeutics Inc and is 27.97% higher over the same period from ACRS
